Epirubicin
- Generic Name
- Epirubicin
- Brand Names
- Ellence, Pharmorubicin PFS
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO11
- CAS Number
- 56420-45-2
- Unique Ingredient Identifier
- 3Z8479ZZ5X
- Background
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
- Indication
For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
- Associated Conditions
- Breast Cancer, Breast Cancer, Stage II, Breast Cancer, Stage III, Colorectal Cancer, Hormone-Refractory Prostate Cancer, Neoplasm of Stomach, Non-Small Cell Lung Carcinoma, Ovarian Cancer, Papillary transitional cell carcinoma of bladder, Recurrent Superficial Bladder Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Carcinoma in situ of urinary bladder
- Associated Therapies
- -
Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2018-09-12
- Lead Sponsor
- University of Pisa
- Target Recruit Count
- 120
- Registration Number
- NCT03668418
- Locations
- 🇮🇹
Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
The Efficacy and Safety of Abraxane Combined With Epirubicin as Neoadjuvant Chemotherapy in Breast Cancer
- First Posted Date
- 2018-08-27
- Last Posted Date
- 2018-12-07
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT03647280
Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer
- First Posted Date
- 2018-06-14
- Last Posted Date
- 2022-01-14
- Lead Sponsor
- Tanvex BioPharma USA, Inc.
- Target Recruit Count
- 809
- Registration Number
- NCT03556358
- Locations
- 🇨🇱
Tanvex Investigational Site 4002, Viña Del Mar, Chile
🇧🇾Tanvex Investigational Site 1007, Babruysk, Mogilev Region, Belarus
🇧🇾Tanvex Investigational Site 1008, Lesnoy, Minsk Region, Belarus
Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer
- First Posted Date
- 2017-12-14
- Last Posted Date
- 2017-12-18
- Lead Sponsor
- Zhiyong Yu
- Target Recruit Count
- 200
- Registration Number
- NCT03373708
Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.
- Conditions
- Interventions
- First Posted Date
- 2017-11-29
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Grand Hôpital de Charleroi
- Target Recruit Count
- 57
- Registration Number
- NCT03356860
- Locations
- 🇧🇪
Grand Hôpital de Charleroi, Charleroi, Hainaut, Belgium
🇧🇪CHU UCL Namur - Sainte-Elisabeth, Namur, Région Wallonne, Belgium
🇧🇪CHU UCL Namur - Site Godinne, Yvoir, Région Wallonne, Belgium
Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy
- First Posted Date
- 2017-11-21
- Last Posted Date
- 2017-11-21
- Lead Sponsor
- Zhiyong Yu
- Target Recruit Count
- 200
- Registration Number
- NCT03349177
Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC
- Conditions
- Interventions
- First Posted Date
- 2017-09-21
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Institut fuer Frauengesundheit
- Target Recruit Count
- 53
- Registration Number
- NCT03289819
- Locations
- 🇩🇪
Department of Gynecology, Tübingen University Hospital, Tübingen, Baden-Württemberg, Germany
🇩🇪Department of Gynecology and Obstetrics, HELIOS Hospital Berlin Buch GmbH, Berlin, Germany
🇩🇪Department for Gynecology and Obstetrics, Marienhospital Bottrop gGmbH, Bottrop, North Rhine-Westphalia, Germany
ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016
- First Posted Date
- 2017-09-18
- Last Posted Date
- 2022-09-28
- Target Recruit Count
- 60
- Registration Number
- NCT03286634
- Locations
- 🇯🇵
Kagoshima University Hospital, Kagoshima, Japan
🇲🇾University of Malaya Medical Centre, Kuala Lumpur, Malaysia
🇲🇾Subang Jaya Medical Centre, Subang Jaya, Malaysia
Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas
- First Posted Date
- 2017-09-11
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Grupo Espanol de Investigacion en Sarcomas
- Target Recruit Count
- 197
- Registration Number
- NCT03277924
- Locations
- 🇮🇹
Istituto Nazionale dei Tumori, Milano, Italy
🇪🇸Hospital Universitario Virgen del Rocío, Sevilla, Spain
🇪🇸Hospital Universitari i Politècnic La Fe, Valencia, Spain
Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-09-06
- Last Posted Date
- 2017-09-06
- Lead Sponsor
- Xijing Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT03273595
- Locations
- 🇨🇳
Xijing Hospital, Xi'an, Shanxi, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.